PE20061199A1 - COMPOSITION CONTAINING CYANOPYRROLIDINE DERIVATIVES FOR SOLID PHARMACEUTICAL PREPARATIONS, SOLID PHARMACEUTICAL PREPARATION CONTAINING THE COMPOSITION AND PROCESS TO PRODUCE THE SOLID PHARMACEUTICAL PREPARATION - Google Patents
COMPOSITION CONTAINING CYANOPYRROLIDINE DERIVATIVES FOR SOLID PHARMACEUTICAL PREPARATIONS, SOLID PHARMACEUTICAL PREPARATION CONTAINING THE COMPOSITION AND PROCESS TO PRODUCE THE SOLID PHARMACEUTICAL PREPARATIONInfo
- Publication number
- PE20061199A1 PE20061199A1 PE2006000103A PE2006000103A PE20061199A1 PE 20061199 A1 PE20061199 A1 PE 20061199A1 PE 2006000103 A PE2006000103 A PE 2006000103A PE 2006000103 A PE2006000103 A PE 2006000103A PE 20061199 A1 PE20061199 A1 PE 20061199A1
- Authority
- PE
- Peru
- Prior art keywords
- solid pharmaceutical
- halogen
- composition
- pharmaceutical preparation
- hydroxyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title 3
- 239000007787 solid Substances 0.000 title 3
- 239000000203 mixture Substances 0.000 title 2
- QJRYYOWARFCJQZ-UHFFFAOYSA-N pyrrolidine-1-carbonitrile Chemical class N#CN1CCCC1 QJRYYOWARFCJQZ-UHFFFAOYSA-N 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical group [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 4
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 abstract 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 150000005846 sugar alcohols Chemical class 0.000 abstract 1
- 150000008163 sugars Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R1 ES HALOGENO, HIDROXILO, ALCOXI C1-C5, ALQUILO C1-C5, ENTRE OTROS; R2 ES H, HALOGENO, HIDROXILO, ALCOXI C1-C5, ENTRE OTROS; R3 Y R4 SON CADA UNO H, HALOGENO, HIDROXILO, ALCOXI C1-C5, ENTRE OTROS; X ES O, S; Y ES -CR5R6-; R5 Y R6 SON CADA UNO H, HALOGENO, ALQUILO C1-C10 SUSTITUIDO O NO, ENTRE OTROS; W ES H, ACILO DERIVADO DE AMINOACIDOS QUE OCURREN NATURALMENTE, ENTRE OTROS; Z ES H, ALQUILO C1-C10 SUSTITUIDO O NO CON HALOGENO, HIDROXILO HIDROXIALQUILO C1-C5, ENTRE OTROS. UN COMPUESTO PREFERIDO ES: SAL DE ACIDO BENCENOSULFONICO DE (2S,4S)-2-CIANO-4-FLUORO-1-[(2-HIDROXI-1,1-DIMETIL)ETILAMINO]ACETILPIRROLIDINA. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE CONTIENE UN ESTABILIZANTE SELECCIONADO ENTRE AZUCARES Y ALCOHOLES DE AZUCAR QUE REDUCE LA DESCOMPOSICION DEL COMPUESTO, Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE LA DIPEPTIDILPEPTIDASA IV (DPPIV) UTILES EN EL TRATAMIENTO DE DIABETES TIPO 2REFERS TO A COMPOUND OF FORMULA I, WHERE R1 IS HALOGEN, HYDROXYL, C1-C5 ALCOXY, C1-C5 ALKYL, AMONG OTHERS; R2 IS H, HALOGEN, HYDROXYL, C1-C5 ALCOXY, AMONG OTHERS; R3 AND R4 ARE EACH H, HALOGEN, HYDROXYL, C1-C5 ALCOXY, AMONG OTHERS; X IS O, S; Y IS -CR5R6-; R5 AND R6 ARE EACH H, HALOGEN, C1-C10 ALKYL SUBSTITUTE OR NOT, AMONG OTHERS; W IS H, ACID DERIVED FROM NATURALLY OCCURRING AMINO ACIDS, AMONG OTHERS; Z IS H, C1-C10 ALKYL SUBSTITUTED OR NOT WITH HALOGEN, HYDROXYL HYDROXYALKYL C1-C5, AMONG OTHERS. A PREFERRED COMPOUND IS: (2S, 4S) -2-CYANE-4-FLUORO-1 - [(2-HYDROXY-1,1-DIMETHYL) ETHYLAMINE] ACETHYLPYRROLIDINE SALT. ALSO REFERRED TO A PHARMACEUTICAL COMPOSITION CONTAINING A STABILIZER SELECTED FROM SUGARS AND SUGAR ALCOHOLS WHICH REDUCES THE DECOMPOSITION OF THE COMPOUND, AND TO A PREPARATION PROCEDURE. SUCH COMPOUNDS ARE USEFUL INHIBITORS OF DIPEPTIDYLPEPTIDASE IV (DPPIV) IN THE TREATMENT OF TYPE 2 DIABETES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005022193A JP2008024592A (en) | 2005-01-28 | 2005-01-28 | Cyanopyrrolidine derivative-containing composition for solid preparation, solid preparation containing the composition and process for producing the solid preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20061199A1 true PE20061199A1 (en) | 2006-11-18 |
Family
ID=36570928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000103A PE20061199A1 (en) | 2005-01-28 | 2006-01-24 | COMPOSITION CONTAINING CYANOPYRROLIDINE DERIVATIVES FOR SOLID PHARMACEUTICAL PREPARATIONS, SOLID PHARMACEUTICAL PREPARATION CONTAINING THE COMPOSITION AND PROCESS TO PRODUCE THE SOLID PHARMACEUTICAL PREPARATION |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP2008024592A (en) |
| AR (1) | AR052197A1 (en) |
| DO (1) | DOP2006000019A (en) |
| PE (1) | PE20061199A1 (en) |
| TW (1) | TW200637815A (en) |
| WO (1) | WO2006080412A2 (en) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4743450A (en) * | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Stabilized compositions |
| CO5150173A1 (en) * | 1998-12-10 | 2002-04-29 | Novartis Ag | COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION |
| US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| TW583185B (en) * | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
| TWI243162B (en) * | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| GB0115517D0 (en) * | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
| AU2002360732A1 (en) * | 2001-12-26 | 2003-07-24 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
| HUP0200849A2 (en) * | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetyl-pyrrolidine-2-carbonitrile derivatives, pharmaceutical compositions containing them and process for producing them |
| TW200401635A (en) * | 2002-07-23 | 2004-02-01 | Yamanouchi Pharma Co Ltd | 2-Cyano-4-fluoropyrrolidine derivative or salt thereof |
| US7304166B2 (en) * | 2002-08-29 | 2007-12-04 | Taisho Pharmaceutical Co., Ltd. | Benzenesulfonate salt of 4-fluoro-2-cyanopyrrolidine derivatives |
| HU227684B1 (en) * | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
| ES2684325T5 (en) * | 2004-01-20 | 2024-06-10 | Novartis Ag | Formulation and direct compression process |
-
2005
- 2005-01-28 JP JP2005022193A patent/JP2008024592A/en active Pending
-
2006
- 2006-01-20 WO PCT/JP2006/301258 patent/WO2006080412A2/en not_active Application Discontinuation
- 2006-01-24 PE PE2006000103A patent/PE20061199A1/en not_active Application Discontinuation
- 2006-01-24 DO DO2006000019A patent/DOP2006000019A/en unknown
- 2006-01-24 AR ARP060100263A patent/AR052197A1/en not_active Application Discontinuation
- 2006-01-25 TW TW095102875A patent/TW200637815A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR052197A1 (en) | 2007-03-07 |
| TW200637815A (en) | 2006-11-01 |
| WO2006080412A3 (en) | 2006-09-21 |
| JP2008024592A (en) | 2008-02-07 |
| WO2006080412A2 (en) | 2006-08-03 |
| DOP2006000019A (en) | 2006-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065806A1 (en) | DERIVATIVES OF QUINOLINA, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES FOR THE TREATMENT OF Rheumatoid ARTHRITIS. | |
| NO20085169L (en) | Crystalline solvates and complexes of (1S) -1,5-anhydro-L-C- (3 - ((phenyl) methyl) phenyl) -D-glucitol derivatives with amino acids as SGLT2 inhibitors for the treatment of diabetes | |
| AR040773A1 (en) | USEFUL PIRAZOLS AS INHIBITORS OF GSK-3 | |
| AR054214A1 (en) | COMPOUNDS DERIVED FROM 1, 1 - DIOXOTIADIAZINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF INFECTION BY THE VIRUS OF HEPATITIS C. | |
| PE20020707A1 (en) | TRIPEPTIDE COMPOUNDS AS INHIBITORS OF THE PROTEASE NS3 OF THE HEPATITIS C VIRUS | |
| UY27317A1 (en) | QUIRAL SALT RESOLUTION | |
| NO20081212L (en) | Xanthine derivatives as selective HM74A agonists | |
| BR0317268A (en) | Pyrazine and 5-substituted pyridine glucokinase activating compounds, pharmaceutical composition, use and process for preparing same | |
| RS20050939A (en) | Pyrido/2,1-a/isoquinoline derivatives as dpp-iv inhibitors | |
| PE20040450A1 (en) | HETEROARYLOXY-ARYL-SPIRO-PYRIMIDINE-2,4,6-TRIONA N-SUBSTITUTED AS METALOPROTEINASE INHIBITORS | |
| BR0312975A (en) | Crystalline form of ß2 adrenergic receptor agonist | |
| UY28578A1 (en) | AMIDA DERIVATIVES | |
| BRPI0314325B8 (en) | aza-bicycloalkyl derivatives, their use, their preparation process and pharmaceutical composition comprising them | |
| BRPI0520252A2 (en) | method of decylating sucralose-6-ester | |
| TW200517389A (en) | Biaryloxymethylarenecarboxylic acids | |
| BR0308993A (en) | Methods for buffer stabilized aqueous deacylation | |
| BR0313831A (en) | Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives | |
| PE20060240A1 (en) | PYRIMIDINE DERIVATIVES TO TREAT ABNORMAL CELLULAR GROWTH | |
| AR087302A1 (en) | SUBSTITUTED HETEROCICLIC AZA DERIVATIVES | |
| Lecerclé et al. | Bacterial transferase MraY inhibitors: Synthesis and biological evaluation | |
| HUT59832A (en) | Process for producing pharmaceutical compositions containing calcitonin | |
| BRPI0512522A (en) | Process for the preparation of esomeprazole sodium salt, compound, pharmaceutical formulation, and treatment method | |
| TW200833371A (en) | Process for solid formulations | |
| HUP0002754A2 (en) | (1s,4r)-cis-4-[2-amino-6-(cyclopropylamino)-9h-purin-9-yl]-2-cyclopentene-1-methanol hemisulfate, process for its production, pharmaceutical compositions of it and intermediates | |
| PE20061199A1 (en) | COMPOSITION CONTAINING CYANOPYRROLIDINE DERIVATIVES FOR SOLID PHARMACEUTICAL PREPARATIONS, SOLID PHARMACEUTICAL PREPARATION CONTAINING THE COMPOSITION AND PROCESS TO PRODUCE THE SOLID PHARMACEUTICAL PREPARATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FX | Voluntary withdrawal |